Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: Soft tissue sarcomas (STS) are rare cancers without validated biomarkers for monitoring or prognosis. Liquid biopsy (LB) enables minimally invasive tumor tracking. Objectives: This study aims to identify prognostic biomarkers in STS by assessing whether copy number variations (CNVs) of key genes correlate with outcomes, enabling early risk stratification and monitoring. Methods: We conducted a preliminary longitudinal CNV analysis in plasma cell-free DNA from 19 patients using droplet digital polymerase chain reaction, measuring CNVs at multiple treatment stages (B1–B6). Statistical analyses were performed in R (v.4.4.3). Continuous variables are shown as median (interquartile range), and categorical variables as counts (%). Benjamini–Hochberg adjustment was applied, and progression-free survival (PFS) was analyzed using Kaplan–Meier and the log-rank test. Results: Associations between CNVs and tumor size, necrosis, treatment response, disease progression, and PFS were observed. B1–B4 showed interconnected CNVs, involving TP53, RB1, MDM2, BRAF, MET, and HSP90. Progression may be associated with elevated CNVs for MDM2 and MET during chemotherapy (B2), and for TP53, RB1, MDM2, and HSP90 following radiotherapy (B3). At baseline, MDM2 CNV was higher in non-responders and increased during therapy in patients who subsequently experienced progression, which may be associated with poorer response to chemotherapy and radiotherapy. A p-value minimization framework suggested gene-specific CNV thresholds at B2 and B3, with higher CNV linked to shorter PFS. Conclusion: Longitudinal LB profiling indicates that genomic changes in STS are linked to outcomes and resistance. MDM2 emerged as a potential biomarker. Given the small, exploratory study cohort, these findings need cautious interpretation and validation in larger groups.
Authors: Aneta Borkowska(Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing), Teresa Szczepińska(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing), Michał Sitek(Formal analysis, Investigation), Wiktoria Trynkos(Formal analysis, Investigation), Izabela Ziuzia-Graczyk(Investigation), Anna Staniszewska(Investigation, Writing – original draft), Łukasz Kuryk(Methodology, Writing – review & editing), Deepak Kala, Deepak Kala, Ewelina Holm Bidstrup, Ewelina Holm Bidstrup, Piotr Rutkowski(Conceptualization, Investigation, Methodology, Writing – review & editing), Monika Staniszewska(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing)
Institutions: The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw University of Technology, Medical University of Warsaw, Central Clinical Hospital, Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy, Institute of High Pressure Physics, Polish Academy of Sciences
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7161733187
